References
- 1.Guan WJ Ni ZY Hu Y et al.Clinical characteristics of coronavirus
disease 2019 in China.N Engl J Med. 2020; (published online Feb
28.)DOI:10.1056/NEJMoa2002032
- .Zhang C Shi L Wang FS Liver injury in COVID-19: management and
challenges.Lancet Gastroenterol Hepatol. 2020; (published
online March)https://doi.org/10.1016/S2468-1253(20)30057-1
- Huang C Wang Y Li X et al.Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395:
497-506
- Marrie RA et al. Dramatically changing rates and reasons for
hospitalization in multiple sclerosis. Neurology. 2014; 83: 929‐ 937.
- Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to
infections in multiple sclerosis patients. Eur J Neurol. 2013; 20:
1153‐ 1160.
- Wijnands JM et al. Infection‐related health care utilization
among people with and without multiple sclerosis. Mult Scler. 2016;
https://doi.org/10.1177/1352458516681198. Epub ahead of print
- Smestad C, Sandvik L, Celius EG. Excess mortality and cause of
death in a cohort of Norwegian multiple sclerosis patients. Mult
Scler. 2009; 15: 1263‐ 1270.
- Wijnands JMA et al. Health‐care use before a first demyelinating
event suggestive of a multiple sclerosis prodrome: a matched cohort
study. Lancet Neurol. 2017; 16: 445‐ 451.
- Bruck W et al. Therapeutic decisions in multiple sclerosis:
moving beyond efficacy. JAMA Neurol. 2013; 70: 1315‐ 1324.
- Global, regional, and national life expectancy, all‐cause
mortality, and cause‐specific mortality for 249 causes of death,
1980‐2015: a systematic analysis for the Global Burden of Disease
Study 2015. Lancet 2016; 388: 1459‐ 1544.
- Williamson EM, Berger JR. Infection risk in patients on multiple
sclerosis therapeutics. CNS Drugs. 2015; 29: 229‐ 244.
- Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. Viral
infections trigger multiple sclerosis relapses: a prospective
seroepidemiological study. J Neurol. 1993; 240: 417‐ 422.
- Faissner S, Gold R Efficacy and Safety of the Newer Multiple
Sclerosis Drugs Approved Since 2010. CNS Drugs. 2018
Mar;32(3):269-287. doi: 10.1007/s40263-018-0488.
- Ellen Lu et al. Safety of disease-modifying drugs for
multiplesclerosis in pregnancy: current challengesand future
considerations for effectivepharmacovigilance. Expert Review of
Neurotherapeutics.
- Randomised double-blind placebo-controlled study of interferon
beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention
of Relapses and Disability by Interferon beta-1a Subcutaneously in
Multiple Sclerosis) Study Group. Lancet Lond. Engl.
1998;352:1498–1504.
- Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind,
dosecomparison study of weekly interferon beta-1a in relapsing MS.Neurology. 2002;59:1507–1517.
- Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and
relapses as a surrogate for disability in multiple sclerosis.Neurology. 2011;77:1684–1690.
- Comi G, Filippi M, Barkhof F, et al. Effect of early interferon
treatment on conversion to definite multiple sclerosis: a randomised
study. Lancet Lond. Engl. 2001;357:1576–1582.
- Davis MD, Ashtamker N, Steinerman JR, et al. Time course of
glatiramer acetate efficacy in patients with RRMS in the GALA study.
Neurol. Neuroimmunol. Neuroinflammation [Internet]. 2017 [cited
2019 Jul 25];
- Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces
relapse rate and improves disability in relapsing-remitting multiple
sclerosis: results of a phase III multicenter, double-blind
placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study
Group. Neurology. 1995;45:1268–1276.
- Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer
acetate on conversion to clinically definite multiple sclerosis in
patients with clinically isolated syndrome (PreCISe study): a
randomised, double-blind, placebo-controlled trial. Lancet Lond.
Engl. 2009;374:1503–1511.
- D’Amico E, Leone C, Caserta C, et al. Oral drugs in multiple
sclerosis therapy: an overview and a critical appraisal. Expert Rev.
Neurother. 2015;15:803–824.
- Oh J, O’Connor PW. Teriflunomide in the treatment of multiple
sclerosis: current evidence and future prospects. Ther. Adv. Neurol.
Disord. 2014;7:239–252.
- O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial
of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J.
Med. 2011;365:1293– 1303.
- Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for
patients with relapsing multiple sclerosis (TOWER): a randomised,
double-blind, placebocontrolled, phase 3 trial. Lancet Neurol.
2014;13:247–256.
- Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for
patients with a first clinical episode suggestive of multiple
sclerosis (TOPIC): a randomised, doubleblind, placebo-controlled,
phase 3 trial. Lancet Neurol. 2014;13:977–986.
- O’Connor P, Comi G, Freedman MS, et al. Long-term safety and
efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO
study. Neurology. 2016;86:920–930. [
- Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis:
latest developments, evidence and place in therapy. Ther. Adv.
Chronic Dis. 2016;7:198– 207.
- Diebold M, Altersberger V, Décard BF, et al. A case of
progressive multifocal leukoencephalopathy under dimethyl fumarate
treatment without severe lymphopenia or immunosenescence. Mult.
Scler. Houndmills Basingstoke Engl. 2019;1352458519852100.
- Safety and efficacy of fingolimod in patients with
relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind,
randomised, placebo-controlled, phase 3 trial. Lancet Neurol.
2014;13:545–556.
- Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5
years) treatment with fingolimod in multiple sclerosis: results from
the extension of the randomised TRANSFORMS study. J. Neurol.
Neurosurg. Psychiatry. 2016;87:468–475.
- Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and
adverse effects in multiple sclerosis. Ann. Neurol. 2011;69:759–777.
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial
of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.
2010;362:416–426.
- Cook S, Vermersch P, Comi G, et al. Safety and tolerability of
cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine
Tablets treating multiple sclerosis orallY) study. Mult. Scler.
Houndmills Basingstoke Engl. 2011;17:578–593